Mice treated with the combination regimen via IMOD showed higher numbers and percentages of CD8+CD3+ effector T (Teff) cells in tumor infiltrating lymphocytes (TILs) (P = 0.00009, Fig. 6a, n = 6–14; Supplementary Fig. 10a; also see immunohistology images of intratumoral CD8+ cells in mice receiving the combination regimen in Supplementary Fig. 10e). This evidence concerns the gene CD8A and neoplasm.